76Bio aims to develop transformational therapies for patients with life-threatening disease by pioneering the next generation of targeted protein degraders.

Allogene Therapeutics is a biotechnology company with a mission to catalyze the next revolution in cancer treatment through the development of allogeneic chimeric antigen receptor T-cell (CAR T) therapy directed at blood cancers and solid tumors. Founded and led by former Kite Pharma executives who bring unrivaled clinical development acumen in cell therapy, Allogene is well-positioned to further the potential of allogeneic cell therapy for patients.

IconOVir Bio is dedicated to the discovery and development of next-generation engineered oncolytic viruses that are potent, tumor-selective and designed for systemic administration. IconOVir applies proprietary high-throughput systems for modular assembly and iterative testing of engineered adenoviruses, enabling rapid optimization of purpose-built oncolytic therapies.

Kronos Bio is dedicated to the research and development of first-in-class therapies that modulate historically recalcitrant cancer targets. Leveraging industry-leading research into high-throughput screening strategies for chemical modulators of transcription factors and other challenging targets in oncology, Kronos utilizes its small molecule microarray (SMM) platform and extensive know-how in biological assay development to pursue novel therapies against some of the most important and intractable targets in cancer research.

Neogene Therapeutics, Inc. is a biomedical company dedicated to developing next-generation T cell therapies that target mutated proteins (neo-antigens) in cancer. Neogene is developing a minimally invasive and scalable platform that will enable targeting of neo-antigens occurring in individual patients with fully personalized and genetically engineered “Designer T cells” that have been optimized to seek and destroy tumor cells based on neo-antigens.